Archive


Category: ~$591M

  • PerkinElmer to Acquire Oxford Immunotec for ~$591M

    Shots: PerkinElmer to acquire Oxford Immunotec for $22/ share with a premium of ~28.3% to the closing price/ share of $17.15 on Jan 5, 2021, making a total deal value $591M. The transaction is expected to be completed in H1’21 The acquisition allows the PerkinElmer to strengthen its portfolio of advanced infectious disease testing solutions […]